AB0412 Preclinical PK and Safety Assessment of the Proposed Adalimumab Biosimilar Gp2017, Compared to Humira®

@article{Kronthaler2014AB0412PP,
  title={AB0412 Preclinical PK and Safety Assessment of the Proposed Adalimumab Biosimilar Gp2017, Compared to Humira®},
  author={U. Kronthaler and M. Baron and J. Poetzl and A. da Silva},
  journal={Annals of the Rheumatic Diseases},
  year={2014},
  volume={73},
  pages={943 - 943}
}
  • U. Kronthaler, M. Baron, +1 author A. da Silva
  • Published 2014
  • Medicine
  • Annals of the Rheumatic Diseases
  • Background TNFα inhibitors are highly effective drugs for the treatment of inflammatory disorders such as rheumatoid arthritis. Biosimilars are approved biologics with comparable quality, safety and efficacy to a reference product, which has lost exclusivity, aiming to offer more affordable treatment to patients. Objectives Here we present results on the pre-clinical in-vivo characterization of the proposed adalimumab biosimilar GP2017 in terms of pharmacokinetics as well as safety. Methods… CONTINUE READING
    2 Citations